NEW DELHI: A single dose of Covaxin from Bharat Biotech in people who had previously been infected with Covid-19 generates an antibody response similar to that provided by two doses of the vaccine in those with no history of infection, a pilot study shows Indian Council for Medical Research (ICMR).
The findings are based on preliminary data and need to be confirmed with large-scale cohort studies, he said.
The study assumes importance because if the ICMR can validate the initial results through a large-scale study, it may be critical to streamline coverage.
“This study provides evidence in support of public health-oriented and immunologically supported vaccination strategies. If our preliminary findings in numerous population studies are confirmed, a single dose of BBV152 vaccine may be recommended to individuals infected with SARS-CoV- 2 previously confirmed, so that naive individuals could get the most benefit from a limited supply of vaccine, ”the paper concludes with the findings of the study published in the Indian Journal of Medical Research.
However, the authors stressed that both doses of vaccine would be ideal even for previously infected individuals in the long run due to the emergence of worrying variants.
Currently, Covaxin from Bharat Biotech is administered in a two-dose regimen with an interval of four to six weeks.
The ICMR study was performed to examine SARS-CoV-2-specific antibody responses after day zero (baseline, before vaccination), day 28 (month 1), and day 56 post-vaccination. first dose (month 2) of Covaxin in a group of health care professionals and front-line workers.
The antibody response of individuals with SARS-CoV-2-confirmed infection prior to vaccination was compared with those individuals with no previous evidence of infection.
The findings are based on preliminary data and need to be confirmed with large-scale cohort studies, he said.
The study assumes importance because if the ICMR can validate the initial results through a large-scale study, it may be critical to streamline coverage.
“This study provides evidence in support of public health-oriented and immunologically supported vaccination strategies. If our preliminary findings in numerous population studies are confirmed, a single dose of BBV152 vaccine may be recommended to individuals infected with SARS-CoV- 2 previously confirmed, so that naive individuals could get the most benefit from a limited supply of vaccine, ”the paper concludes with the findings of the study published in the Indian Journal of Medical Research.
However, the authors stressed that both doses of vaccine would be ideal even for previously infected individuals in the long run due to the emergence of worrying variants.
Currently, Covaxin from Bharat Biotech is administered in a two-dose regimen with an interval of four to six weeks.
The ICMR study was performed to examine SARS-CoV-2-specific antibody responses after day zero (baseline, before vaccination), day 28 (month 1), and day 56 post-vaccination. first dose (month 2) of Covaxin in a group of health care professionals and front-line workers.
The antibody response of individuals with SARS-CoV-2-confirmed infection prior to vaccination was compared with those individuals with no previous evidence of infection.